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Abstract 1 
The nitric oxide synthase (NOS) independent pathway of nitric oxide (NO) production in which 2 
nitrite (NO2-) is reduced to NO may have therapeutic applications for those with cardiovascular 3 
diseases in which the NOS pathway is downregulated. We tested the hypothesis that NO2- 4 
infusion would reduce mean arterial pressure (MAP) and increase skeletal muscle blood flow 5 
(BF) and vascular conductance (VC) during exercise in the face of NOS blockade via L-NAME. 6 
Following infusion of L-NAME (10 mg · kg-1: L-NAME), male Sprague-Dawley rats (3-6 7 
months, n=8) exercised without (L-NAME) and after infusion of  sodium NO2- (7 mg · kg-1:, L-8 
NAME + NO2-). MAP and hindlimb skeletal muscle BF (radiolabeled microsphere infusions) 9 
were measured during submaximal treadmill running (20 m · min-1, 5% grade). Across group 10 
comparisons were made with a published control dataset (n=11). Relative to L-NAME, NO2- 11 
infusion significantly reduced MAP (P<0.03). The lower MAP in L-NAME+NO2- was not 12 
different from healthy control animals (control: 137 ± 3 L-NAME: 157 ± 7, L-NAME + NO2-: 13 
136 ± 5 mmHg). Also, NO2- infusion significantly increased VC when compared to L-NAME 14 
(P<0.03), ultimatly negating any significant differences from control animals (control: 0.78 ± 15 
0.05, L-NAME: 0.57 ± 0.03, L-NAME + NO2-; 0.69 ± 0.04 ml · min-1 · 100 g-1 · mmHg-1) with 16 
no apparent fiber type preferential effect. Overall hindlimb BF was decreased significantly by L-17 
NAME: however, in L-NAME+NO2- BF improved to a level not significantly different from 18 
healthy controls (control: 108 ± 8, L-NAME: 88 ± 3, L-NAME + NO2-: 94 ± 6 ml · min-1 · 100 g-19 
1, P=0.38 L-NAME vs. L-NAME + NO2-). Individuals with diseases that impair NOS activity, 20 
and thus vascular function, may benefit from a NO2- based therapy in which NO bioavailability 21 
is elevated in a NOS-independent manner. 22 
 23 
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Abbreviations list: ANOVA, analysis of variance; BF, blood flow; CHF, chronic heart failure; 1 
LSD, least significant difference; MAP, mean arterial pressure; NO, nitric oxide; NO2-, nitrite; 2 
NO3-, nitrate; NOS, nitric oxide synthase; O2, oxygen; PO2mv, microvascular partial pressure of 3 
oxygen; QO2, oxygen delivery; VC, vascular conductance; , oxygen uptake. 4 
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Introduction 1 
The cardiovascular response to exercise is characterized by a multitude of neural, humoral 2 
and mechanical components serving to elevate cardiac output and redistribute blood flow (BF), 3 
and thus O2 delivery (QO2), to contracting myocytes. Of the humoral regulators, the ubiquitous 4 
signaling molecule nitric oxide (NO) plays a fundamental role in the hyperemic response to 5 
exercise and, as a result, its bioavailability is key to elicit the changes in QO2 necessary to meet 6 
the rapidly rising O2 demand ( ) of the skeletal muscle (reviewed by 1). Indeed, disease states 7 
hallmarked by reduced NO bioavailability (i.e. chronic heart failure, CHF, reviewed by 2) 8 
demonstrate a robust disruption in spatial and temporal skeletal muscle QO2, resulting in 9 
perturbed metabolic function and compromised exercise tolerance. 10 
NO is synthesized endogenously in a reaction catalyzed by the NO synthase (NOS) family of 11 
enzymes or the one-step reduction of nitrite (NO2-) to NO; the latter being a NOS-independent 12 
pathway (reviewed by 3). Recent evidence from murine models suggests that the bioactivity of 13 
NO2- may be upregulated via ingestion of nitrate (NO3-) rich food stuffs (i.e. beetroot juice), thus 14 
likely elevating NO bioavailability (following the reduction of NO3- to NO2- and finally NO) 15 
resulting in improved skeletal muscle vascular, metabolic 4-6, and contractile 7 function. These 16 
results extend to humans as several laboratories have demonstrated ergogenic effects of dietary 17 
NO3- supplementation in healthy 8-13 and diseased 14-17 populations. Interestingly, while these 18 
studies employ a dietary means of increasing endogenous [NO2-], vasoactivity of the directly 19 
infused anion is evident in humans 18-21 and animals 22-25 suggesting that bolus delivery may 20 
afford an expedited method of augmenting vascular and metabolic control in vivo.  21 
Bearing in mind the beneficial impacts of dietary NO3- supplementation on exercise 22 
performance, and the vascular effects of NO2- infusion highlighted above it is logical to consider 23 
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that direct infusion with NO2- may also impact skeletal muscle vascular control during exercise. 1 
Furthermore, when considering that NO2- reduction to NO is potentiated in low PO2 and/or pH 2 
environments 18, bioactivity of NO2- may be further facilitated (or relied upon) when NOS 3 
function is reduced or completely abolished and O2 transport is impaired (as is the case in many 4 
pathological conditions). If direct NO2- infusion augments exercising skeletal muscle vascular 5 
function independent of NOS, NO2- therapy could emerge as an attractive means of restoring NO 6 
bioavailability in various cardiovascular diseases in which NOS function is compromised.  7 
Despite these prospects, there are no investigations into the effects of NO2- infusion on 8 
exercising skeletal muscle vascular control under conditions of NOS blockade. Therefore, the 9 
purpose of this investigation was to determine the impact(s) of NO2- infusion on skeletal muscle 10 
vascular control during exercise in rats with NOS blockade elicited via L-NAME. We tested the 11 
hypothesis that, relative to the L-NAME condition, treatment with NO2- would restore exercising 12 
mean arterial pressure (MAP) and total exercising hindlimb skeletal muscle BF and vascular 13 
conductance (VC) to values observed in healthy young-adult rats (with intact NOS function).  14 
  15 
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Methods 1 
Ethical approval 2 
All procedures employed in this investigation were approved by the Institutional Animal 3 
Care and Use Committee of Kansas State University and were conducted under the guidelines 4 
established by The Journal of Physiology 26. Sixteen young adult male Sprague-Dawley rats (~3 5 
months of age, Charles River Laboratories, Wilmington, MA, USA) were maintained at 6 
accredited animal facilities at Kansas State University on a 12:12-hr light-dark cycle with food 7 
and water provided ad libitum. All rats were familiarized with running on a custom-built motor-8 
driven treadmill for 5 min · day-1 at a speed of 20 m · min-1 up a 5% grade for ~5 days. In an 9 
effort to minimize the unnecessary utilization of additional animals, control BF, VC, blood gas, 10 
[lactate], and plasma [NO2-]/[NO3-] values reported herein represent animals from recently 11 
published work (n=11, 27) and followed the same experimental procedures as detailed below. 12 
Surgical instrumentation 13 
On the day of the experiment, rats were anaesthetized initially with a 5% isoflurane-O2 14 
mixture and maintained subsequently on 3% isoflurane/O2 mixture. A catheter (PE-10 connected 15 
to PE-50, Intra-Medic polyethylene tubing, Clay Adams Brand, Becton, Dickinson and 16 
Company, Sparks, MD, USA) was placed in the ascending aorta via the right carotid artery. A 17 
second catheter was surgically placed in the caudal (tail) artery as described previously 28. Both 18 
catheters were tunneled subcutaneously through the dorsal aspect of the cervical region and 19 
exteriorized via a puncture wound in the skin. The incisions were closed, anesthesia was 20 
terminated and the rats were given a minimum of 60 min to recover 29. 21 
L-NAME infusion 22 
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Rats were then placed on the treadmill and, following a ~5 minute resting period,  NG-1 
nitro-L arginine methyl ester (10 mg · kg-1, L-NAME; n=8, Sigma Chemical, St. Louis, MO, 2 
USA) was administered to each rat via the caudal artery catheter to inhibit NOS. This dose has 3 
been used extensively in our laboratory and has demonstrated inhibition of NOS via attenuation 4 
of acetylcholine induced reductions in MAP 30,31.  5 
Exercise protocol and measurement of hindlimb skeletal muscle BF 6 
Following L-NAME infusion, the caudal artery catheter was connected to a 1 ml syringe 7 
chambered in a Harvard infusion/withdrawal pump (model 907, Cambridge, MA, USA) and the  8 
carotid artery catheter was connected to a pressure transducer (Gould Statham P23ID, Valley 9 
View, OH, USA) maintained at the same height as the animal. Approximately 3 min post-L-10 
NAME infusion, exercise was initiated and treadmill speed was increased progressively over a 11 
~30 s period to a speed of 20 m · min-1 (5% grade, ~60% max; 32). The rats continued to 12 
exercise for another 2.5 min until a total time of 3 min was reached. At 3 min the Harvard pump 13 
was activated and withdrawal was initiated at a rate of 0.25 ml · min-1. Simultaneously, HR and 14 
MAP were measured and recorded. The carotid artery catheter was then disconnected from the 15 
pressure transducer and 0.5-0.6 × 106 15 μm diameter radiolabeled microspheres (57Co or 85Sr in 16 
random order; Perkin Elmer, Waltham, MA, USA) were infused into the aortic arch for 17 
determination of regional BF (L-NAME condition). Following the microsphere infusion, ~0.3 ml 18 
of blood was sampled from the carotid artery catheter for the determination of blood [lactate] 19 
(Nova Stat Profile M, Nova Biomedical, Waltham, MA, USA) and exercise was terminated. 20 
NO2- infusion 21 
Following a 30 min recovery period a bolus infusion of sodium NO2-  22 
(7 mg · kg-1 body mass, L-NAME + NO2-; n=8, Sigma Chemical, St. Louis, MO, USA) was 23 
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administered to each rat via the caudal artery catheter. The exercise and microsphere infusion 1 
protocols (radio-labeled differently from the first) were then repeated (condition L-NAME + 2 
NO2-).  3 
Blood sampling and measurement of plasma [NO3-] and [NO2-] 4 
Immediately following microsphere infusion but prior to the termination of exercise, a 5 
~0.3 ml blood sample was drawn from the carotid artery catheter for determination of blood pH, 6 
PO2, and %O2 saturation (Nova Stat Profile M, Nova Biomedical, Waltham, MA, USA). For 7 
plasma [NO3-] and [NO2-], following the termination of exercise ~0.8 ml of blood was drawn 8 
into heparinized tubes and rapidly centrifuged at 5000 g at 4°C for 6 minutes. Plasma was then 9 
extracted and frozen immediately at -80°C for later analysis via chemiluminescence as described 10 
previously 4,5,27,33. 11 
Determination of BF and VC 12 
Rats were euthanized via pentobarbital sodium overdose (≥50 mg · kg-1). The thorax of 13 
each rat was opened and accurate placement of the carotid artery catheter was confirmed before 14 
the internal organs and 28 individual muscles and muscle parts of the hindlimb were excised.  15 
Radioactivity of each tissue was determined with a gamma scintillation counter (Packard 16 
Auto Gamma Spectrometer, model 5230, Downers Grove, IL, USA). Tissue BF was then 17 
calculated using the reference sample method 28 and expressed as ml · min-1 · 100g-1. VC was 18 
then calculated by normalizing BF to MAP and expressed as ml · min-1 · 100g-1 · mmHg-1.  19 
Statistical analysis 20 
Results were compared among (control vs. L-NAME and control vs. L-NAME + NO2-) 21 
and within (L-NAME vs. L-NAME + NO2-) groups using a priori unpaired and paired one-tail 22 
10 
 
Student’s t tests, respectively, corrected for multiple comparisons. Values are expressed as mean 1 
± SEM.  2 
   3 
  4 
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Results 1 
MAP, HR, plasma [NO3-] and [NO2-] and blood gases 2 
Relative to control, post NO2- infusion plasma [NO2-] (control: 0.17 ± 0.2, L-NAME + 3 
NO2-: 306.8 ± 38.7 µMol, P<0.01) and [NO3-] (control: 17.8 ± 1, L-NAME + NO2-: 152.5 ± 35 4 
µMol, P<0.01) were significantly elevated. Relative to control, MAP was significantly higher in 5 
the L-NAME condition (Figure 1, P<0.03). Following NO2- infusion, MAP was reduced 6 
significantly when compared to the L-NAME condition (P<0.03). Exercising MAP was not 7 
different between control and L-NAME+NO2- groups (P=0.36). Relative to the control and L-8 
NAME+NO2- conditions, exercising HR was significantly lower in the L-NAME condition 9 
(control: 528 ± 12, L-NAME: 493 ± 37, L-NAME + NO2-: 520 ± 33 beats · min-1, P<0.01).  10 
There were no differences in arterial PO2, PCO2, or %O2 saturation during exercise. 11 
Arterial blood [lactate] during exercise was greater following NO2- infusion (3.8 ± 0.5 mM) 12 
compared to control (2.7 ± 0.4 mM) and L-NAME only (2.1 ± 0.3 mM) conditions, (P<0.016).  13 
BF and VC 14 
 L-NAME significantly reduced exercising total hindlimb skeletal muscle BF and VC 15 
(Figure 2, P<0.03). Following NO2- infusion total hindlimb skeletal muscle VC was restored to 16 
levels observed in control rats (Figure 2, P<0.03 L-NAME vs. L-NAME+NO2-, P>0.10 control 17 
vs. L-NAME+NO2). There were no differences in total hindlimb skeletal muscle BF during 18 
exercise in L-NAME vs. L-NAME + NO2- or control vs. L-NAME + NO2- conditions (Figure 2 19 
bottom panel, P>0.03).  20 
Relative to control, L-NAME treated rats had lower BF in 5 and VC in 15 of the 28 21 
individual hindlimb muscles and muscle parts, whereas this was the case for only 3 muscles (BF 22 
and VC) in the L-NAME+NO2- condition (Table 1, P<0.03 for all). Moreover, following NO2- 23 
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infusion, VC in 19 of the 28 individual hindlimb muscles and muscle parts was increased 1 
significantly when compared to the L-NAME condition (P<0.03, Table 1). 2 
Relative to control, BF and VC were lower in the adrenals and pancreas while VC was 3 
lower in the kidneys, stomach, and small intestine in rats treated with L-NAME (P<0.03, Table 4 
2). Following NO2- infusion, renal and adrenal BF and VC were lower when compared to control 5 
animals while renal and adrenal BF was reduced when compared to L-NAME (P<0.03, Table 2). 6 
 7 
 8 
 9 
  10 
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4. Discussion 1 
The principal original finding of this investigation is that, in the face of NOS blockade, 2 
NO2- infusion restored exercising MAP and hindlimb skeletal muscle VC to levels observed in 3 
young-adult healthy rats with intact NOS function. While NO2- infusion did not increase BF 4 
when compared to the L-NAME condition, it did abolish the lower BF induced by L-NAME. 5 
Elevations in VC and reductions in MAP could serve to reduce afterload and thus reduce the 6 
work of the heart during exercise. These results demonstrate that NO2- may serve as a powerful 7 
modulator of vascular control in vivo, independent of NOS function and thus may hold 8 
promising therapeutic potential, particularly in diseases with impaired NOS function and 9 
chronically elevated MAP. 10 
Effects of inorganic NO2- infusion on skeletal muscle BF and VC and MAP 11 
An abundance of research has focused on defining the vasoactive/cardioprotective role(s) 12 
of NO2- with many studies suggesting that the reduction of NO2- to NO compliments the well 13 
understood NOS pathway of NO production, particularly when NOS function becomes 14 
uncoupled or otherwise impaired (reviewed by 34,35). The vascular responses to NO2- infusion 15 
presented herein support this notion. Similar to what has been reported previously in our 16 
laboratory 36,37, infusion with the comprehensive NOS blocker L-NAME increased MAP ~15% 17 
and decreased skeletal muscle VC ~26% during exercise. Consistent with our hypothesis, 18 
infusion with NO2- (7mg · kg-1) restored MAP and VC to levels similar to those observed in 19 
healthy control animals. One potential explanation for these effects of NO2- could be the lower 20 
PO2/pH environment present within the skeletal muscle following NOS inhibition 33. Such 21 
environments facilitate (or uninhibit) NO2- reduction to NO in vivo 18,38, which may allow local 22 
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NO2- to support the blood-myocyte PO2 gradient (via ↑QO2 and microvasculature PO2, PO2mv) 1 
that, when compromised, leads to tissue hypoxia and exacerbates intracellular perturbations 39. 2 
One striking aspect of this investigation, in which acute NO2- infusion was employed, 3 
was that the augmented skeletal muscle VC was observed in muscles and muscle parts that span 4 
the full spectrum of fast and slow twitch fibre types (Table 1). This is in contrast to 5 
investigations utilizing short-term dietary NO3- supplementation as a means of increasing 6 
circulating [NO2-]. Specifically, there is a fibre type preferential effect of dietary NO3- 7 
supplementation as rats given NO3- rich beetroot juice for 5 days exhibited elevated skeletal 8 
muscle BF and VC exclusively in muscles and muscle portions comprised of  ≥ 66% type IIb + 9 
d/x muscle fibres 27. Moreover, beetroot juice elevates PO2mv during muscle contractions in the 10 
gastrocnemius (fast twitch) but not soleus (slow twitch) muscles 33. The substantial array of 11 
muscles and muscle portions exhibiting a vasoactive response to NO2- infusion herein suggests 12 
that the fibre type preferential effects observed following dietary NO3- supplementation may be 13 
conferred via changes in protein expression which require a longer period of elevated NO2- 14 
exposure to manifest. This idea is supported by evidence from Hernandez, Schiffer, Ivarsson, 15 
Cheng, Bruton, Lundberg, Weitzberg, Westerblad 7 in which the improvements in fast twitch 16 
skeletal muscle force production evoked by NO3- supplementation were attributed to elevations 17 
in calcium handling proteins (i.e. calsequestrin 1 and the dihydropyridine receptor) which were 18 
present following multiple days of dietary NO3- supplementation.  19 
Additionally, the discrepancies in the vascular responses to NO3- vs. NO2- treatment 20 
could be related to the relative impacts of NOS inhibition in fast vs. slow twitch muscles. 21 
Skeletal muscles comprised predominantly of slow twitch fibres demonstrate the greatest deficits 22 
in BF and VC following L-NAME infusion 36 likely due to a greater expression of endothelial 23 
15 
 
NOS (eNOS) within these tissues 40. These slow twitch muscles may exhibit much greater BF 1 
and than their fast twitch counterparts both at rest and during exercise (~100% greater for 2 
both BF and  41). Consequently, NOS inhibition may have crippled O2 delivery in these 3 
muscles sufficiently enough to produce an environment ripe for NO2- bioactivation (i.e. very low 4 
PO2 and pH). This effect could place more emphasis on NO2- as the primary source of NO in 5 
these specific tissues when vascular function is impaired, as it is in many disease states 42. In this 6 
regard, the spatial changes in VC seen following NO2- infusion herein may mimic closely what 7 
would be observed in individuals with diseases that compromise NOS function. However, these 8 
questions require further investigation using specific models of vascular disease. 9 
Clinical and Therapeutic implications 10 
In healthy individuals eNOS is the primary endogenous source for NO2- and NO 43. 11 
Endothelial dysfunction becomes evident early on in many diseases including CHF (reviewed by 12 
2) and peripheral artery disease (reviewed by 44) and thus likely limits vascular and metabolic 13 
function via attenuated NO production from both NOS dependent and independent pathways 14 
43,45. As evidenced by Hirai et al. 46,47, reduced NO from NOS dramatically impairs the matching 15 
of skeletal muscle QO2 to such that superfusion of L-NAME in the contracting rat 16 
spinotrapezius muscle transforms the healthy PO2mv profile into one resembling CHF 46. In this 17 
regard, the blockade of NOS induced by L-NAME infusion performed in the present 18 
investigation presents a challenge that mimics the consequences of CHF, and potentially other 19 
diseases. Therefore, from the present findings, a therapy in which systemic [NO2-] is elevated 20 
(via endogenous or exogenous sources) may provide beneficial vascular responses independent 21 
of NOS function. Even small improvements in vascular function may enhance metabolic control 22 
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during dynamic exercise; potentially improving adherence to rehabilitation programs 35, which 1 
in-and-of themselves would upregulate eNOS function and endogenous NO2- production. 2 
Experimental considerations and Potential limitations 3 
A surprising result of the present investigation was the rise in exercising blood [lactate] 4 
following NO2- infusion (~41% and 81% greater vs. control and L-NAME respectively). Lower 5 
levels of NO may act as a useful brake on mitochondrial activity via competitive binding to 6 
complex IV of the respiratory chain 48. In contrast, high concentrations of NO have been 7 
associated with adverse effects on cell respiration via nitrosylation of mitochondrial electron 8 
chain complexes, specifically complex I 49. In addition NO works to inhibit complex IV 9 
(cytochrome oxidase) thereby reducing cellular O2 consumption. Both of these effects may prove 10 
beneficial in certain environments or situations when O2 delivery becomes reduced as reductions 11 
in tissue work to extend the PO2 gradient across a larger tissue area, effectively sharing the 12 
available O2 50. However, in the current study it is possible that the rate of NO2- reduction to NO 13 
became high enough to overwhelm mitochondrial respiration, thus leading to impaired oxidative 14 
metabolism and an increased reliance on glycolytic means of ATP production. In addition, while 15 
the current dose of NO2- raised plasma [NO3-] to levels very similar to what has been reported 16 
following dietary NO3- supplementation in humans 9,14 and animals 5,27 the plasma [NO2-] were 17 
much greater than that achieved via NO3- supplementation, and thus may have contributed to the 18 
aforementioned effect on metabolism. In this regard a comprehensive dose-response relationship 19 
will need to be determined before NO2- can be used as an effective therapeutic. 20 
Furthermore, considering that NOS was acutely inhibited in the present investigation, the 21 
impacts of NO2- infusion may differ when administered to specific models of vascular diseases 22 
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that have been developed chronically, as this would more closely mimic specific etiologies. 1 
Additionally, due to the relatively long half-life and bioactivity of L-NAME metabolites (~20 2 
hours in rats 51) the experimental design was limited to a fixed sequence and therefore, an 3 
ordering effect cannot be ruled out. Future investigations in which NO2- is employed in healthy 4 
control animals would also provide further insight into the bioactivity of NO2- in animals with 5 
intact NOS function and could shed light on how a NO2- based intervention may impact healthy 6 
cardiovascular function.  7 
Conclusions 8 
These data highlight the potential for NO2- to act independently of NOS and improve 9 
skeletal muscle vascular control during exercise. Considering the multiple cardiovascular 10 
diseases that impair NOS function, therapies that increase [NO2-] may result in improved skeletal 11 
muscle vascular control during exercise. However, the NO2- induced changes in blood [lactate] 12 
seen during exercise herein suggests that the reduction of NO3- to NO2-, accomplished via 13 
facultative anaerobes in the mouth following dietary NO3- consumption, may provide the 14 
controlled release of NO2- needed to elicit the most beneficial vascular and metabolic changes 15 
during exercise. It is anticipated that future investigations into the vascular impacts of both NO2- 16 
and NO3- based therapies will provide crucial insight into the potential benefits, and limitations, 17 
of both interventions.  18 
19 
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Table 1 Effects NO2- infusion (7 mg · kg-1) on exercising hindlimb skeletal muscle BF (ml · min-1 · 100g-
1) and VC (ml · min-1 · 100g-1 · mmHg-1) in rats with NOS blockade (L-NAME).  
          BF           VC 
 Control L-NAME L-NAME+NO2
-  Control L-NAME L-NAME+NO2- 
Ankle extensors        
Soleus (9%) 295 ± 42 242 ± 71 285 ± 36  2.14 ± 0.30 1.56 ± 0.17 2.06 ± 0.23 
Plantaris (80%) 207 ± 15 144 ± 8* 173 ± 15  1.50 ± 0.10 0.93 ± 0.06* 1.27 ± 0.08 
Gastrocnemius, red (14%) 452 ± 44 333 ± 59 362 ± 65  3.27 ± 0.30 2.18 ± 0.02* 2.63 ± 0.44 
Gastrocnemius, white (100%) 42 ± 7 26 ± 3 37 ± 4  0.30 ± 0.05 0.17 ± 0.02* 0.27 ± 0.03 
Gastrocnemius, mixed (91%) 149 ± 12 120 ± 5 141 ± 8  1.08 ± 0.08 0.77 ± 0.04* 1.04 ± 0.04 
Tibialis posterior (73%) 118 ± 17 81 ± 12 91 ± 13  0.85 ± 0.12 0.51 ± 0.07* 0.66 ± 0.09 
Flexor digitorum longus (68%) 99 ± 14 60 ± 7* 69 ± 9  0.71 ± 0.09 0.38 ± 0.04* 0.51 ± 0.06 
Flexor halicus longus (71%) 75 ± 10 68 ± 8 99 ± 14  0.54 ± 0.06 0.44 ± 0.06 0.74 ± 0.11 
        
Ankle flexors        
Tibialis anterior, red (63%) 343 ± 35 209 ± 10* 219 ± 20*  2.48 ± 0.23 1.36 ± 0.10* 1.62 ± 0.14* 
Tibialis anterior, white (80%) 119 ± 14 83 ± 6* 89 ± 12  0.86 ± 0.09 0.54 ± 0.05* 0.66 ± 0.09 
Extensor digitorum longus (76%) 54 ± 7 75 ± 20 77 ± 17  0.39 ± 0.05 0.50 ± 0.14 0.57 ± 0.13 
Peroneals (67%) 128 ± 11 72 ± 14* 91 ± 13*  0.93 ± 0.08 0.46 ± 0.09* 0.67 ± 0.09* 
        
Knee extensors        
Vastus intermedius (4%) 359 ± 39 257 ± 25 302 ± 39  2.60 ± 0.27 1.66 ± 0.17* 2.20 ± 0.25 
Vastus medialis (82%) 114 ± 18 137 ± 13 144 ± 14  0.82 ± 0.12 0.89 ± 0.08 1.06 ± 0.08 
Vastus lateralis, red (35%) 388 ± 43 310 ± 35 281 ± 25  2.82 ± 0.29 2.02 ± 0.26 2.08 ± 0.52 
Vastus lateralis, white (100%) 33 ± 5 26 ± 8 31 ± 7  0.24 ± 0.03 0.16 ± 0.04 0.23 ± 0.04 
Vastus lateralis, mixed (89%) 167 ± 21 123 ± 12 127 ± 13  1.22 ± 0.14 0.81 ± 0.09* 0.94 ± 0.09 
Rectus femoris, red (66%) 224 ± 33 181 ± 15 204 ± 17  1.62 ± 0.23 1.17 ± 0.10 1.50 ± 0.11 
Rectus femoris, white (100%) 101 ± 13 81 ± 7 91 ± 8  0.73 ± 0.09 0.52 ± 0.05 0.67 ± 0.06 
        
Knee flexors        
Biceps femoris anterior (100%) 50 ± 8 33 ± 4 36 ± 4  0.36 ± 0.05 0.21 ± 0.03* 0.27 ± 0.03 
Biceps femoris posterior (92%) 79 ± 8 65 ± 3 71 ± 5  0.58 ± 0.06 0.42 ± 0.02* 0.53 ± 0.04 
Semitendinosus (83%) 56 ± 6 34 ± 3* 37 ± 4*  0.40 ± 0.04 0.22 ± 0.02* 0.28 ± 0.03* 
Semimembranosus, red (72%) 119 ± 14 86 ± 7 83 ± 14  0.87 ± 0.09 0.56 ± 0.05* 0.62 ± 0.11 
Semimembranosus, white (100%) 33 ± 6 38 ± 7 40 ± 11  0.24 ± 0.04 0.25 ± 0.05 0.30 ± 0.09 
        
Thigh adductors        
Adductor longus (5%) 315 ± 38 263 ± 26 231 ± 31  2.28 ± 0.26 1.71 ± 0.21 1.68 ± 0.22 
Adductor magnus & brevis (89%) 83 ± 8 80 ± 7 80 ± 9  0.60 ± 0.05 0.52 ± 0.05 0.60 ± 0.06 
Gracilis (77%) 42 ± 4 37 ± 4 34 ± 5  0.30 ± 0.03 0.24 ± 0.02 0.26 ± 0.04 
Pectineus (69%) 54 ± 8 40 ± 6 46 ± 11  0.39 ± 0.06 0.25 ± 0.03 0.34 ± 0.08 
        
Data are mean ± SEM. Values in parentheses indicate % type IIb + d/x according to Delp & Duan (1996). 
Control: n=11, L-NAME: n=8, L-NAME + NO2-: n=8. *P<0.03 vs. control. P<0.03 vs. L-NAME. 
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Table 2.  Effects of NO2- infusion (7 mg · kg-1) on exercising BF (ml · min-1 · 100g-1) and VC (ml · min-1 · 
100g-1 · mmHg-1) in the kidneys and organs of the splanchnic region. 
  BF  VC 
  Control L-NAME L-NAME + NO2  Control L-NAME L-NAME + NO2 
Kidney  421 ± 42 338 ± 28 267 ± 31*  3.05 ± 0.28 2.22 ± 0.25* 1.96 ± 0.22* 
Stomach  67 ± 13 38 ± 3 35 ± 4  0.49 ± 0.10 0.25 ± 0.02* 0.25 ± 0.03 
Adrenals  353 ±  72 128 ± 17* 100 ± 66*  2.87 ± 0.44 0.85 ± 0.14* 0.72 ± 0.15* 
Spleen  61 ± 14 102 ± 21 48 ± 7  0.44 ± 0.10 0.68 ± 0.16 0.35 ± 0.06 
Pancreas  110 ± 15 72 ± 8* 93 ± 22  0.80 ± 0.11 0.47 ± 0.06* 0.67 ± 0.15 
Sm. intestine  240 ± 27 177 ± 24 211 ± 26  1.74 ± 0.18  1.17 ± 0.19* 1.55 ± 0.17 
Lg. intestine  127 ± 16 123 ± 20 140 ± 42  0.92 ± 0.10 0.82 ± 0.15 1.01 ± 0.28 
Liver**  16 ± 4 15 ± 2 13 ± 3  0.12 ± 0.02 0.10 ± 0.01 0.09 ± 0.02 
Data are mean ± SEM.  **Indicates arterial, not portal, BF and VC. Control: n=11, L-NAME: n=8, L-
NAME + NO2-: n=8. *P<0.03 vs. control. P<0.03 vs. L-NAME. 
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Figure captions 
Figure 1. Exercising MAP, systolic blood pressure (SBP), diastolic blood pressure (DBP) and 
pulse pressure (PP) values for control, L-NAME and L-NAME+NO2- conditions. *P<0.03 vs. 
control, #P<0.03 vs. L-NAME. Note: control values represented are from previously published 
data. 
Figure 2. Total hindlimb skeletal muscle BF and VC for control, L-NAME and L-NAME+NO2- 
conditions in rats during submaximal locomotory exercise. *P<0.03 vs. control, #P<0.03 vs. L-
NAME. Note: control values represented are from previously published data. 
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